AstraZeneca

#AstraZeneca #Covid-19 #Marketing approval authorisation #MHRA

Covid-19 approval milestone for those who can’t be vaccinated 

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first antibody combination for pre-exposure prophylaxis (PrEP) against Covid-19 licensed in Great Britain.   The use of this medicine is for adults who are not currently… Read More

#News #Trending News

#Asthma #AstraZeneca #Clinical trials

New data reinforce efficacy of asthma drug 

Results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated reductions in the annualised asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 According to the company, these findings support… Read More

#News

Kidneys
#AstraZeneca #Diabetes #Drug approvals

NICE recommends AstraZeneca drug for adult chronic kidney disease  

The National Institute for Health and Care Excellence (NICE) in the UK has issued a Final Appraisal Document (FAD) recommending AstraZeneca’s Forxiga (dapagliflozin) within its marketing authorisation for the treatment of adults with chronic kidney disease (CKD).1  Conditions  Dapagliflozin is recommended as an option… Read More

#News

EU flag
#AstraZeneca #Drug approvals

AstraZeneca drug for SLE patients approved in the EU 

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.   Context   Saphnelo is the first biologic for SLE approved in… Read More

#News

#AstraZeneca #Biobanking #Genetics #Genomics

Rare variant contribution to human disease  

Listen to this article on the DDW Podcast: Slavé Petrovski and Andrew Harper, Centre for Genomics Research, AstraZeneca, outline the implications and insight offered by the recent publication of an AstraZeneca-authored paper “Rare variant contribution to human disease in 281,104 UK Biobank exomes”.  In August 2021, Nature published… Read More

#Exclusive Content #News #Opinion #Trends & Analysis

Lung cancer
#AstraZeneca #Lung cancer #Oncology

Success for AstraZeneca lung cancer therapy 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1  Context  Lung… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug targets #Immunology

AstraZeneca uses AI platform to target idiopathic pulmonary fibrosis 

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its drug development portfolio, discovered using BenevolentAI’s platform. This is reportedly the second novel target from the collaboration that has been identified, validated, and selected for AstraZeneca’s portfolio.   The collaboration  BenevolentAI’s collaboration with AstraZeneca currently focuses… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug development #Funding #Research #Technology

Next wave of innovation: AstraZeneca £1bn R&D centre 

AstraZeneca has unveiled The Discovery Centre (DISC) in Cambridge, UK – a research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.  The new £1 billion facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus… Read More

#News

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

Health Canada approves Moderna, Pfizer and AstraZeneca vaccines 

Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria.  “Health Canada’s approval of our Covid-19 vaccine is an important milestone as… Read More

#Covid-19 #News #Regulatory

#AstraZeneca #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

SK bioscience and GSK start trial of Covid-19 vaccine 

SK bioscience (SK) and GlaxoSmithKline (GSK) have initiated a Phase III clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results.  The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to… Read More

#News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#AstraZeneca #Cancer research #Clinical trials #Institute of Cancer Research

First medicine approved in the EU to treat rare genetic condition

AstraZeneca and MSD’s Koselugo (selumetinib) has been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. NF1 is a debilitating genetic condition affecting one in 3,000 individuals worldwide. In 30-50%… Read More

#News

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis